Эндопротезирование тазобедренных суставов у пациентов с системной красной волчанкой
Аннотация
Системная красная волчанка (СКВ) – системное аутоиммунное ревматическое заболевание неизвестной этиологии, характеризующееся гиперпродукцией органонеспецифических аутоантител к различным компонентам клеточного ядра и развитием иммуновоспалителъного повреждения внутренних органов. Особое место в спектре поражений суставов у пациентов с СКВ занимает остеонекроз (ОН), который рассматривается как тяжелое осложнение заболевания. Достигнутые в последнее время успехи в диагностике и лечении СКВ, значительное повышение выживаемости пациентов диктуют необходимость поддержания адекватного качества жизни больных. При ОН тазобедренных суставов (ТБС) тотальное эндопротезирование (ТЭ) является основным методом хирургической коррекции, позволяющим контролировать боль, улучшить качество жизни и функциональную способность пациентов. Несмотря на довольно длительную историю применения данного метода, проблема оценки долгосрочных результатов ТЭ ТБС и частоты развития послеоперационных осложнений у пациентов с СКВ до конца не изучена.
Об авторах
В. В. Муханов
ФГБУ «Федеральный научно-клинический центр специализированных
видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства»
Россия
115682, Москва, Ореховый бульвар, 28
Россия
115682, Москва, Ореховый бульвар, 28
А. В. Рыбников
ФГБУ «Федеральный научно-клинический центр специализированных
видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства»
Россия
115682, Москва, Ореховый бульвар, 28
Россия
115682, Москва, Ореховый бульвар, 28
Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А2
Россия
115522, Москва, Каширское шоссе, 34А2
М. А. Макаров
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А2
Россия
115522, Москва, Каширское шоссе, 34А2
Список литературы
1. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
2. Насонов ЕЛ, редактор. Системная красная волчанка. В кн.: Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 113-41.
3. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-30. doi: 10.1038/nrrheum.2016.186
4. Lo MS, Tsokos GC. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol. 2018;30(2):222-8. doi: 10.1097/BOR.0000000000
5. Nightingale AL, Davidson JE, Molta CT, et al. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med. 2017;4(1):e000172. doi: 10.1136/lupus-2016-000172
6. Yang Y, Kumar S, Lim LS, et al. Risk factors for symptomatic avascular necrosis in childhood-onset systemic lupus erythematosus. J Rheumatol. 2015;42:2304-9. doi: 10.3899/jrheum.150464
7. Mont MA, Pivec R, Banerjee S, et al. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty. 2015;30(9):1506-12.e5. doi: 10.1016/j.arth.2015.03.036
8. Gontero PR, Bedoya ME, Benavente E, et al. Osteonecrosis in systemic lupus erythematosus. Rheumatol Clin. 2015;11:151-5. doi: 10.1016/j.reumae.2014.05.006
9. Joo YB, Sung YK, Shim JS, et al. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study. Rheumatol Int. 2015;35:879-86. doi: 10.1007/s00296-014-3147-3
10. Lee J, Kwok SK, Jung SM, et al. Osteonecrosis of the hip in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus. 2014;23:39-45. doi: 10.1177/0961203313512880
11. Kunyakham W, Foocharoen C, Mahakkanukrauh A, et al. Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Pac J Allergy Immunol. 2012;30:152-7.
12. Sayarlioglu M, Yuzbasioglu N, Inanc M, et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int. 2012;32:177-82. doi: 10.1007/s00296-010-1597-9
13. Al Saleh J, El Sayed M, Salah N, et al. Predictors of avascular necrosis of the hip in Emiratis patients with systemic lupus erythematosus. Egypt J Immunol. 2010;17:29-40.
14. Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus. 2018;27(1):76-81. doi: 10.1177/0961203317711012
15. Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol. 2003;25:13-24. doi: 10.1385/CRIAI:25:1:13
16. Prasad R, Ibanez D, Gladman DD, Urowitz MB. The role of non-corticosteroid related factors in osteonecrosis (ON) in SLE: a nested case–control study of inception patients. Lupus. 2007;16:157-62. doi: 10.1177/0961203306075771
17. Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60:1145-8. doi: 10.1136/ard.60.12.1145
18. Jones LC, Mont MA. Osteonecrosis (avascular necrosis of bone) [Internet]. Waltham, MA: UpToDate; 2018. Mar 21 [cited 2018 Apr 22]. Available at: www.uptodate.com/contents/osteonecrosisavascular-necrosis-of-bone
19. Moya-Angeler J, Gianakos AL, Villa JC, et al. Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015 Sep 18;6(8):590-601. doi: 10.5312/wjo.v6.i8.590
20. Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med. 2015;8:201-9. doi: 10.1007/s12178-015-9277-8
21. Fukushima W, Fujioka M, Kubo T, et al. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 2010;468:2715-24. doi: 10.1007/s11999-010-1292-x
22. Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of osteonecrosis in systemic lupus erythematosus: A systematic review and metaanalysis. J Rheumatol. 2018;45(10):1462-76. doi: 10.3899/jrheum.170837
23. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, et al. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:761-5.
24. Gurion R, Yang H, Li H. Risk factors for the development of avascular necrosis in pediatric systemic lupus erythematosus patients [abstract]. Arthritis Rheum. 2013;65:S536-7.
25. Houssiau FA, N’Zeusseu Toukap A, Depresseux G, et al. Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol. 1998;37:448-53. doi: 10.1093/rheumatology/37.4.448
26. Castro TC, Lederman H, Terreri MT, et al. The use of joint-specific and whole-body MRI in osteonecrosis: a study in patients with juvenile systemic lupus erythematosus. Br J Radiol. 2011;84:621-8. doi: 10.1259/bjr/34972239
27. Dimant J, Ginzler EM, Diamond HS, et al. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol. 1978;5:136-41.
28. Faezi ST, Hoseinian AS, Paragomi P, et al. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study. Mod Rheumatol. 2015;25:590-4. doi: 10.3109/14397595.2014.987366
29. Fialho SC, Bonfa E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus. 2007;16:239-44. doi: 10.1177/0961203307076771
30. Hagiwara S, Nakamura J, Watanabe A, et al. Corticosteroids and low bone mineral density affect hip cartilage in systemic lupus erythematosus patients: Quantitative T2 mapping. J Magn Reson Imaging. 2015;42:1524-31. doi: 10.1002/jmri.24953
31. Migliaresi S, Picillo U, Ambrosone L, et al. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus. 1994;3:37-41. doi: 10.1177/096120339400300108
32. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998;37:895-900. doi: 10.1093/rheumatology/37.8.895
33. Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol. 1997;24:2318-22. doi: 10.1016/S0883-5403(97)90075-9
34. Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. J Rheumatol. 1989;16:604-8.
35. Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24:654-62.
36. Massardo L, Jacobelli S, Leissner M, et al. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus. 1992;1:401-5. doi: 10.1177/096120339200100610
37. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995;8:137-45. doi: 10.1002/art.1790080305
38. Fernandes EG, Guissa VR, Saviolli C, et al. Osteonecrosis of the jaw on imaging exams of patients with juvenile systemic lupus erythematosus. Rev Bras Reumatol. 2010;50:3-15. doi: 10.1590/S0482-50042010000100002
39. Griffiths ID, Maini RN, Scott JT. Clinical and radiological features of osteonecrosis in systemic lupus erythematosus. Ann Rheum Dis. 1979;38:413-22. doi: 10.1136/ard.38.5.413
40. Li X, Ren Q, Chen Z, et al. Risk factors for avascular necrosis in patients with systemic lupus erythematosus [abstract]. Int J Rheum Dis. 2013;16 Suppl 1:1-48.
41. Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med. 1978;138:750-4. doi: 10.1001/archinte.1978.03630290052018
42. Smith FE, Sweet DE, Brunner CM, Davis JS 4th. Avascular necrosis in SLE. An apparent predilection for young patients. Ann Rheum Dis. 1976;35:227-32. doi: 10.1136/ard.35.3.227
43. Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P. Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol. 2009;15:345-9. doi: 10.1097/RHU.0b013e3181ba3423
44. Zizic TM, Marcoux C, Hungerford DS, et al. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med. 1985;79:596-604. doi: 10.1016/0002-9343(85)90057-9
45. Klippel JH, Gerber LH, Pollak L, Decker JL. Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecrosis. Am J Med. 1979;67:83-7. doi: 10.1016/0002-9343(79)90077-9
46. Nagasawa K, Ishii Y, Mayumi T, et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis. 1989;48:672-6. doi: 10.1136/ard.48.8.672
47. Sheikh JS, Retzinger GS, Hess EV. Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis. Lupus. 1998;7:42-8. doi: 10.1191/096120398678919732
48. Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop. 1998;27:352-4.
49. Calvo-Alen J, McGwin G, Toloza S, et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis. 2006;65:785-90. doi: 10.1136/ard.2005.040428
50. Nakamura J, Ohtori S, Sakamoto M, et al. Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence. Clin Exp Rheumatol. 2010;28:13-8.
51. Schrezenmeier E, Dö rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Feb 7. doi: 10.1038/s41584-020-0372-x
52. Seleznick MJ, Silveira LH, Espinoza LR. Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol. 1991;18:1416-7.
53. Crome CR, Rajagopalan S, Kuhan G, Fluck N. Antiphospholipid syndrome presenting with acute digital ischaemia, avascular necrosis of the femoral head and superior mesenteric artery thrombus. BMJ Case Rep. 2012;2012. doi: 10.1136/bcr-2012-006731
54. Lykissas MG, Gelalis ID, Kostas-Agnantis IP, et al. The role of hypercoagulability in the development of osteonecrosis of the femoral head. Orthop Rev (Pavia). 2012;4(2):e17. doi: 10.4081/or.2012.e17
55. El-Gendy H, El-Gohary RM, Mahfouz S, et al. Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature. Platelets. 2019;30(5):664-71. doi: 10.1080/09537104.2018.1535701
56. Cecchi I, Perez Sanchez L, Sciascia S, Roccatello D. Multifocal avascular osteonecrosis despite appropriate anticoagulation therapy in a patient with systemic lupus erythematosus and antiphospholipid syndrome. BMJ Case Rep. 2018;2018. doi: 10.1136/bcr-2018-225532
57. Hisada R, Kato M, Ohnishi N, et al. Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(4):645-9. doi: 10.1093/rheumatology/key365
58. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. doi: 10.1002/art.33340
59. Yang XY, Xu DH. MDR1(ABCB1) gene polymorphisms associated with steroid induced osteonecrosis of femoral head in systemic lupus erythematosus. Pharmazie. 2007;62:930-2.
60. Zhang K, Zheng Y, Jia J, et al. Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis. Clin Rheumatol. 2018;37(1):5-11. doi: 10.1007/s10067-017-3820-5
61. Kasturi S, Goodman S. Current perspectives on arthroplasty in systemic lupus erythematosus: rates, outcomes, and adverse events. Curr Rheumatol Rep. 2016;18(9):59. doi: 10.1007/s11926-016-0608-6
62. Kennedy JW, Khan W. Total hip arthroplasty in systemic lupus erythematosus: a systematic review. Int J Rheumatol. 2015;2015:475489. doi: 10.1155/2015/475489
63. Chen CH, Hsu CW, Lu MC. Risk of joint replacement surgery in Taiwanese female adults with systemic lupus erythematosus: a population-based cohort study. BMC Musculoskelet Disord. 2019;20(1):314. doi: 10.1186/s12891-019-2698-6
64. Mukherjee S, Culliford D, Arden N, Edwards C. What is the risk of having a total hip or knee replacement for patients with lupus? Lupus. 2015;24:198-202. doi: 10.1177/0961203314547894
65. Mertelsmann-Voss C, Lyman SL, Pan T, et al. Arthroplasty rates are increased among us patients with systemic lupus erythematosus: 1991–2005. J Rheumatol. 2014;41:1-8. doi: 10.3899/jrheum.130617
66. Kang Y, Zhang Z, Zhao X, et al. Total hip arthroplasty for vascular necrosis of the femoral head in patients with systemic lupus erythematosus: a midterm follow-up study of 28 hips in 24 patients. Eur J Orthop Surg Traumatol. 2013;23:73-9. doi: 10.1007/s00590-012-0939-6
67. Issa K, Naziri Q, Rasquinha VJ, et al. Outcomes of primary total hip arthroplasty in systemic lupus erythematosus with a proximally-coated cementless stem. J Arthroplasty. 2013;28(9):1663-6. doi: 10.1016/j.arth.2013.02.024
68. Shigemura T, Kishida S, Iida S, et al. Cementless total hip arthroplasty for osteonecrosis of the femoral head in systemic lupus erythematosus: a study with 10–16 years of follow-up. Eur Orthopaed Traumatol. 2013;4(1):15-20. doi: 10.1007/s12570-012-0149-z
69. Ito H, Matsuno T, Hirayama T, et al. Health-related quality of life in patients with systemic lupus erythematosus after medium to long-term follow-up of hip arthroplasty. Lupus. 2007;16(5):315-23. doi: 10.1177/0961203307077989
70. Chen YW, Chang JK, Huang KY, et al. Hip arthroplasty for osteonecrosis in patients with systemic lupus erythematosus. Kaohsiung J Med Sci. 1999;15(12):697-703. doi: 10.1016/S1010-7940(99)00064-0
71. Brinker MR, Rosenberg AG, Kull L, Galante JO. Primary total hip arthroplasty using noncemented porous-coated femoral components in patients with osteonecrosis of the femoral head. J Arthroplasty. 1994;9(5):457-68. doi: 10.1016/0883-5403(94)90091-4
72. Low CK, Lai CH, Low YP. Results of total hip replacement in systemic lupus erythematosus. Singapore Med J. 1991;32(6):391-2.
73. Hanssen AD, Cabanela ME, Michet CJ. Hip arthroplasty in patients with systemic lupus erythematosus. J Bone Joint Surg Am. 1987;69:807-14. doi: 10.2106/00004623-198769060-00003
74. Chen PG, Lin CC. Total hip arthroplasty in patients with systemic lupus erythematosus. J Formosan Med Assoc. 1987;86(3):299-306.
75. Merayo-Chalico J, Gonzalez-Contreras M, Ortiz Hernandez R, et al. Total hip arthroplasty outcomes: An 18-year experience in a single center: is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplasty. 2017. doi: 10.1016/j.arth.2017.06.021
76. Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi: 10.3899/jrheum.151373
77. Lin J-A, Liao C-C, Lee Y-J, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi: 10.1136/annrheumdis-2012-202758
78. Papa MZ, Shiloni E, Vetto JT, et al. Surgical morbidity in patients with systemic lupus erythematosus. Am J Surg. 1989;157:295-8. doi: 10.1016/0002-9610(89)90554-0
79. Schnaser EA, Browne JA, Padgett DE, et al. Perioperative complications in patients with inflammatory arthropathy undergoing total hip arthroplasty. J Arthroplasty. 2016;31:2286-90. doi: 10.1016/j.arth.2016.03.023
80. Gholson JJ, Wilkinson BG, Brown TS, et al. Systemic lupus erythematosus is a risk factor for complications in total joint arthroplasty. Iowa Orthop J. 2018;38:183-90.
81. Mak A. Orthopedic surgery and its complication in systemic lupus erythematosus. World J Orthop. 2014;5:38-44. doi: 10.5312/wjo.v5.i1.38
82. Fein AW, Figgie CA, Dodds TR, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after total knee arthroplasty. JCR J Clin Rheumatol. 2016;22:355-9. doi: 10.1097/RHU.0000000000000435
83. Issa K, Pierce TP, Scillia AJ, et al. Midterm outcomes following total knee arthroplasty in lupus patients. J Arthroplasty. 2016;31:655-7. doi: 10.1016/j.arth.2015.09.049
84. Shah UH, Mandl LA, Mertelsmann-Voss C, et al. Systemic lupus erythematosus is not a risk factor for poor outcomes after total hip and total knee arthroplasty. Lupus. 2015;24:900-8. doi: 10.1177/0961203314566635
85. Макаров СА, Павлов ВП. Перипротезное инфицирование после эндопротезирования тазобедренного сустава при ревматических заболеваниях. Научно-практическая ревматология. 2013;51(6):711-3. doi: 10.14412/1995-4484-2013-711-3
86. Li Z, Du Y, Xiang S, et al. Risk factors of perioperative complications and transfusion following total hip arthroplasty in systemic lupus erythematosus patients. Lupus. 2019;28(9):1134-40. doi: 10.1177/0961203319862609
87. Singh JA, Cleveland JD. Lupus is associated with poorer outcomes after primary total hip arthroplasty. Lupus. 2019;28(7):834-42. doi: 10.1177/0961203319851573
88. Храмов АЭ, Макаров МА, Макаров СА и др. Интраоперационные перипротезные переломы при эндопротезировании тазобедренного сустава у больных ревматическими заболеваниями. Научно-практическая ревматология. 2018;56(6):791-6. doi: 10.14412/1995-4484-2018-791-796
Для цитирования:
Муханов В.В., Рыбников А.В., Попкова Т.В., Макаров М.А. Эндопротезирование тазобедренных суставов у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2020;58(2):191-197. https://doi.org/10.14412/1995-4484-2020-191-197
For citation:
Mukhanov V.V., Rybnikov A.V., Popkova T.V., Makarov M.A. HIP ARTHROPLASTY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology Science and Practice. 2020;58(2):191-197. (In Russ.) https://doi.org/10.14412/1995-4484-2020-191-197
Просмотров: 408
Послать статью по эл. почте 
